Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 15, 2009, Pages 2545-2554

  Bertino, Joseph S ^a,b   Zhang, Jin Zhong ^c,d  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b BERTINO CONSULTING   (United States)

^c BAUSCH AND LOMB   (United States)

^d ST JOHN FISHER COLLEGE   (United States)

Author keywords

Bacterial conjunctivitis; Bacterial resistance; Besifloxacin ophthalmic suspension 0.6 ; Besivance ; Fluoroquinolone

Indexed keywords

AZITHROMYCIN; BESIFLOXACIN; BESIVANCE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOMICROSCOPY; BLURRED VISION; CLINICAL FEATURE; CONJUNCTIVITIS; CONTROLLED STUDY; DISEASE TRANSMISSION; DNA REPLICATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ERADICATION THERAPY; EYE INFECTION; EYE IRRITATION; EYE PAIN; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MONKEY; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NONHUMAN; OCULAR PRURITUS; PICORNAVIRUS; PUNCTATE KERATITIS; RABBIT; REVIEW; RISK REDUCTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; AZEPINES; CLINICAL TRIALS AS TOPIC; CONJUNCTIVITIS, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; OPHTHALMIC SOLUTIONS; QUINOLINES;

EID: 70349397427     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903213413     Document Type: Review

References (49)

1. Hovding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008;86:5-17
2. Rose P. Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin Pharmacother 2007;8:1903-1921 (Pubitemid 47316148)
3. Wilhelmus KR. The red eye. Infectious conjunctivitis, keratitis, endophthalmitis, and periocular cellulitis. Infect Syndr Head Neck 1988;2:99-116
4. Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician 1998;57:735-746
5. Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2006;2:CD001211
6. Diamant JI, Hwang DG. Therapy for bacterial conjunctivitis. Ophthalmol Clin North Am 1999;12:15-20
7. Ohnsman CM. Exclusion of students with conjunctivitis from school: policies of state departments of health. J Pediatr Ophthalmol Strabismus 2007;44:101-105
8. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989;2:378-424
9. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol 2004;49(Suppl 2):S73-8
10. Mah FS. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol 2004;15:316-320
11. Scoper SV. Review of third- and fourth-generation fluoroquinolones in ophthalmology: in vitro and in vivo efficacy. Adv Ther 2008;25:979-994
12. Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008;145:951-958
13. Asbell PA, Sahm DF, Shaw M, et al. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005. J Cataract Refract Surg 2008;34:814-818
14. Blomquist PH. Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006;104:322-345
15. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003;3:359-371
16. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol 2004;49(Suppl 2):S79-83
17. Levinson BA, Rutzen AR. New antimicrobials in ophthalmology. Ophthalmol Clin North Am 2005;18:493-509
18. Cavuoto K, Zutshi D, Karp CL, et al. Update on bacterial conjunctivitis in South Florida. Ophthalmology 2008;115:51-56
19. Miller D, Flynn PM, Scott IU, et al. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol 2006;124:479-483
20. Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Infect Control 2006;34:S38-45
21. Buznach N, Dagan R, Greenberg D. Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era. Pediatr Infect Dis J 2005;24:823-828 (Pubitemid 41324892)
22. Brown L. Resistance to ocular antibiotics: an overview. Clin Exp Optom 2007;90:258-262
23. Ward KW, Lepage J-F, Driot J-Y. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther 2007;23:243-256
24. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005;41(Suppl 2):S120-6
25. Cambau E, Matrat S, Pan XS, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 2009;63:443-450
26. Yague G, Morris JE, Pan X-S, et al. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob Agents Chemother 2002;46:413-419
27. Zhang J-Z, Cavet ME, Ward KW. Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells. Curr Eye Res 2008;33:923-932
28. Zhang J-Z, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother 2008;61:111-116
29. Protzko E, Bowman L, Abelson M, et al. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci 2007;48:3425-3429
30. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 1999;12:147-179 (Pubitemid 29055958)
31. Blondeau JM, Borsos S, Hesje CK. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus. J Chemother 2007;19:146-151 (Pubitemid 46697733)
32. Haas W, Pillar CM, Zurenko GE, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 2009;53:3552-3560
33. Haas W, Zurenko GE, Lee J, et al. Activity of besifloxacin and comparators against ciprofloxacin resistant Staphylococcus aureus and Staphylococcus epidermidis ocular isolates from 2005-2008. Poster presented at the 3rd Congress of the Federation of European Microbiologists (FEMS), 28 June - 2 July 2009 Goteborg, Sweden
34. Haas W, Brunner LS, Pillar C, Morris TW. Bactericidal activity of besifloxacin and other ophthalmic antibacterials against recent ocular isolates. Invest Ophthalmol Vis Sci 2009;50:e-abstract 2675
35. Proksch J, Driot J-Y, Ward KW. Nonclinical ocular and systemic pharmacokinetics of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. Invest Ophthalmol Vis Sci 2007;48:e-abstract 4273
36. Proksch JW, Granvil CP, Siou-mermet R, et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther 2009;25:335-344
37. Allen GP, Kaatz GW, Rybak MJ. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int J Antimicrob Agents 2004;24:150-160
38. Metzler K, Hansen GM, Hedlin P, et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 2004;24:161-167 (Pubitemid 38993695)
39. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000;46:669-683
40. Proksch JW, Chappa AK, Haas W, Morris TW. Besifloxacin, moxifloxacin, and gatifloxacin ocular tissue AUC/MIC ratios for fluoroquinolone-resistant organisms. Invest Ophthalmol Vis Sci 2009;50:e-abstract 2673
41. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin 2009;25:1159-1169
42. Karpecki P, DePaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther 2009;31:514-526
43. McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology 2009. [Epub 2009 July 28]
44. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol 1991;112(Suppl 4):29-33S
45. Morris TW, Hass W, Brunner LS, et al. Clinical efficacy of besifloxacin ophthalmic suspension; integrated microbiological analysis of 3 trials for topical treatment of bacterial conjunctivitis. Invest Ophthalmol Vis Sci 2009;50:e-abstract 5945
46. McDonald MB, Blondeau JM, DeCory HH, et al. Multidrug-resistant strains in clinical trials of besifloxacin in the treatment of bacterial conjunctivitis. Poster presented at the Annual Meeting of the American Academy of Ophthalmology, 8 - 11 November 2008 Atlanta, GA, USA
47. Paterno MR, Comstock TL, Lynch JA, Usner DW. Besifloxacin ophthalmic suspension 0.6% is safe and well tolerated in the treatment of bacterial conjunctivitis. Invest Ophthalmol Vis Sci 2009;50:e-abstract 2674
48. US Food and Drug Administration. Division of Anti-Infective and Ophthalmologic Products Advisory Committee Meeting: Briefing package for besifloxacin hydrochloride ophthalmic suspension for the treatment of bacterial conjunctivitis. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/ 2008-4397b1-01-FDA.pdf [Last accessed 12 February 2009]
49. Besivance [package insert]. Rochester, NY: Bausch & Lomb, Inc.